Human papillomaviruses (HPV) can cause benign or malignant disease with the majority of
infections without symptoms. The viral origin of cervical cancer is now proven with HPV …

Context.—Impact studies of the new human papillomavirus (HPV) vaccines will be biased
unless local baseline distribution studies are conducted. Vaccine cross protection for other …

Context.—A cascade of molecular tests for human papillomavirus (HPV), as a follow-up to
Papanicolaou test screening, could eliminate unnecessary colposcopy. Tests based on …

Abstract The ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV study
evaluated the clinical usefulness of the cobas HPV Test (Roche Molecular Systems …

The effective management of women with human papillomavirus (HPV)-positive, cytology-
negative results is critical to the introduction of HPV testing into cervical screening. HPV …

Objective High-risk human papillomavirus (HR-HPV) infection is a leading cause of cervical
cancer, of which human papillomavirus (HPV)-16 and HPV-18 account for about 70% of …

BACKGROUND: Human papillomavirus (HPV) types 16 and 18 are the 2 most frequent
types associated with cervical cancer. Identifying their presence or absence in cervical …

Human papillomavirus (HPV) is the etiologic agent for cervical cancer with HPV type 16
(HPV16) being found in about 50% of cervical cancers worldwide. HPVs vary in genomic …

Objective. There are currently 2 tests approved for clinical use that nonspecifically detect the
presence of multiple oncogenic or high-risk human papillomavirus (HPV) types. One HPV …

Background Racial and ethnic variations in attribution of cervical precancer and cancer to
human papillomavirus (HPV) types may result in different HPV vaccine protection, screening …